OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors, has announced it will be presenting at the Annual
Rodman & Renshaw 2013 Global Investment Conference in New York City.
Punit Dhillon, President and CEO of OncoSec Medical, will provide a
company overview and will be available to participate in one-on-one
meetings with investors who are registered to attend the conference.
The presentation will take place on Monday, September 9 at 2:25 PM ET at
Room 7.02, 7th Floor of the Millennium Broadway Hotel in New
York, NY. The presentation will also be webcast and can be viewed at
this link: http://wsw.com/webcast/rrshq23/ONCS.
The webcast replay will remain available for 90 days following the live
presentation.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors. ImmunoPulse and NeoPulse therapies address an
unmet medical need and represent a potential solution, for less invasive
and less expensive therapies that are able to minimize detrimental
effects resulting from currently available cancer treatments such as
surgery, systemic chemotherapy or immunotherapy and other treatment
alternatives. OncoSec Medical's core technology is based upon its
proprietary use of an electroporation platform to enhance the delivery
and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse)
or chemotherapeutic agent (NeoPulse). Treatment of various solid
cancers using these targeted anti-cancer agents has
demonstrated selective destruction of cancerous cells while potentially
sparing healthy normal tissues during early and late stage clinical
trials. OncoSec's clinical programs include three Phase II clinical
trials for ImmunoPulse targeting lethal skin cancers. More information
is available at http://www.oncosec.com/.
About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an
informational service and networking opportunity for companies and
investors. Rodman does not prepare, review or edit the presentations and
other information provided by each company, and does not take any
responsibility for the accuracy or adequacy of any such information as
the basis for any investment decision. Rodman is not providing any
person with any investment advice through their participation in or
attendance of the Conference, nor is Rodman soliciting any offers to buy
or sell any security of any company.
This press release contains forward looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward looking statements." Forward looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties which may cause our results to differ
materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ from those predicted include our ability to raise additional
funding, our ability to acquire, develop or commercialize new products,
uncertainties inherent in pre-clinical studies and clinical trials,
unexpected new data, safety and technical issues, competition and market
conditions. These and additional risks and uncertainties are more fully
described in OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward looking
statements which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward looking
statements to reflect new information, events or circumstances after the
date they are made, or to reflect the occurrence of unanticipated events.
Copyright Business Wire 2013